Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

200884 citationsJournal Articlebronze Open Access

Authors

The combination of doxorubicin 60 mg/m(2) followed by trabectedin 1.1 mg/m(2) every 21 days is safe and active in patients with soft-tissue sarcoma.

Good health and well-being

Published in: Clinical Cancer Research

Volume 14, Issue 20, pp. 6656-6662

Field-Weighted Citation Impact: 7.08